Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 12, 2015, Pages 505.e1-505.e7

  Poli, Giulia ^a   Brancorsini, Stefano ^a   Cochetti, Giovanni ^a   Barillaro, Francesco ^a   Egidi, Maria Giulia ^a   Mearini, Ettore ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bladder cancer; Cytokeratin; Gene expression; Inflammasome

Indexed keywords

BETA ACTIN; CRYOPYRIN; CYTOKERATIN 20; INFLAMMASOME; MESSENGER RNA; NEURONAL APOPTOSIS INHIBITORY PROTEIN; NLRP4 PROTEIN; NLRP9 PROTEIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL COUNT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; UPREGULATION; URINE SEDIMENT; BLADDER TUMOR; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMASOMES; KERATIN-20; MALE; MIDDLE AGED; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 85003881496     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.07.012     Document Type: Article

References (30)

1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., et al. Cancer incidence and mortality patterns in Europe. Estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
2. Têtu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009, 22:S53-S59.
3. Ye F., Wang L., Castillo-Martin M., McBride R., Galsky M.D., Zhu J., et al. Biomarkers for bladder cancer management: present and future. Am J Clin Exp Urol 2014, 2:1-14.
4. Vrooman O.P.J., Witjes J.A. Urinary markers in bladder cancer. Eur Urol 2008, 53:909-916.
5. Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol 1995, 8:384-388.
6. Moll R., Löwe A., Laufer J., Franke W.W. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992, 140:427-447.
7. Guo B., Luo C., Xun C., Xie J., Wu X., Pu J. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR. Exp Oncol 2009, 31:43-47.
8. Yildiz I.Z., Recavarren R., Armah H.B., Bastacky S., Dhir R., Parwani A.V. Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies. Diagn Pathol 2009, 4:35.
9. Pina-Cabral L., Santos L., Mesquita B., Amaro T., Magalhães S., Criado B. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clin Transl Oncol 2007, 9:731-736.
10. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
11. Zitvogel L., Kepp O., Galluzzi L., Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012, 13:343-351.
12. Ahirwar D.K., Agrahari A., Mandhani A., Mittal R.D. Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 2009, 14:213.
13. Guirado M., Gil H., Saenz-Lopez P., Reinboth J., Garrido F., Cozar J.M., et al. Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer. Hum Immunol 2012, 73:668-672.
14. Motta V., Soares F., Sun T., Philpott D.J. NOD-like receptors: versatile cytosolic sentinels. Physiol Rev 2015, 95:149-178.
15. Henao-Mejia J., Elinav E., Strowig T., Flavell R.A. Inflammasomes: far beyond inflammation. Nat Immunol 2012, 13:321-324.
16. Verma D., Bivik C., Farahani E., Synnerstad I., Fredrikson M., Enerbäck C., et al. Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma. Pigment Cell Melanoma Res 2012, 25:506-513.
17. Voronov E., Dotan S., Krelin Y., Song X., Elkabets M., Carmi Y., et al. Unique versus redundant functions of IL-1α and IL-1β in the tumor microenvironment. Front Immunol 2013, 4:177.
18. Ungerbäck J., Belenki D., Jawad ul-Hassan A., Fredrikson M., Fransén K., Elander N., et al. Genetic variation and alterations of genes involved in NFκB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis 2012, 33:2126-2134.
19. UICC International Union Against Cancer TNM classification of malignant tumors. TNM classification of malignant tumors 2009, 262-265. Wiley-Blackwell. L.H. Sobin, M. Gospodariwicz, C. Wittekind (Eds.).
20. MacLennan G.T., Kirkali Z., Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007, 51:889-898.
21. Babjuk M., Böhle A., Burger M., Compérat E., Kaasinen E., Palou J., et al. EAU guidelines on non-muscle-invasive bladder cancer. Eur Urol 2011, 59:584-594.
22. Southgate J., Harnden P., Trejdosiewicz L.K. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol 1999, 14:657-664.
23. Sun Y., He H., Ma Q., Wang X.Y., Yang L., He D.L. Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis. Zhonghua Yi Xue Za Zhi 2005, 85:2507-2512.
24. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2013, 12:298-306.
25. Olbert P.J., Kesch C., Henrici M., Subtil F.S., Honacker A., Hegele A., et al. TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells. Urol Oncol 2015, 33:e19-e27.
26. Hagerling C., Casbon A.J., Werb Z. Balancing the innate immune system in tumor development. Trends Cell Biol 2015, 25:214-220.
27. Hughes F.M., Vivar N.P., Kennis J.G., Pratt-Thomas J.D., Lowe D.W., Shaner B.E., et al. Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation. Am J Physiol Renal Physiol 2014, 306:F299-F308.
28. Lage S.L., Longo C., Branco L.M., da Costa T.B., Buzzo Cde L., Bortoluci K.R. Emerging concepts about NAIP/NLRC4 inflammasomes. Front Immunol 2014, 5:309.
29. Chen X., Wang T., Yang D., Wang J., Li X., He Z., et al. Expression of the IAP protein family acts cooperatively to predict prognosis in human bladder cancer patients. Oncol Lett 2013, 5:1278-1284.
30. Vucic D., Fairbrother W.J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007, 13:5995-6000.